Diagnostics: diagnosis based on information from sources such as findings from a physical examination, interview with the patient or family or both, medical history of the patient and family, and clinical findings as reported by laboratory tests and radiologic studies. Differential diagnosis involves the process of weighing the probability of one disease versus that of other diseases possibly accounting for a patient's illness. The differential diagnosis of rhinitis (a runny nose) includes allergic rhinitis (hayfever), the abuse of nasal decongestants and, of course, the common cold.
DATE: October 27th, 2020 TIME: 6:00am PT Bruker proudly introduces the latest member of the MALDI Biotyper® product family, the MALDI Biotyper sirius one. Bruker‘s newest sirius sy...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: October 21, 2020 Time: 8:00am PDT Learning Objectives Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provider of continuing educ...
Date: October 20, 2020 Time: 5:00am (PDT), 8:00am (EDT), 2:00pm (CEST) With the COVID-19 pandemic as one of the biggest challenges to our modern world, Bruker has taken an active part suppor...
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
DATE: October 14, 2020 TIME: 10:00am PT Do you need help in planning your drug testing protocols? Did you know that a “one size fits all” approach to drug testing does not apply...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
Date: October 13, 2020 Time: 5:00am (PDT), 8:00am (EDT) Dr. Markus Kostrzewa shall ellaborate the progress that has been made in Bruker Microbiology Research and Development, including new p...
DATE: October 09, 2020 TIME: 08:00am PT Traditional culture techniques, as the primary diagnostic tool for infectious diseases, are coming under scrutiny for failing to universally detect in...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
DATE: October 27th, 2020 TIME: 6:00am PT Bruker proudly introduces the latest member of the MALDI Biotyper® product family, the MALDI Biotyper sirius one. Bruker‘s newest sirius sy...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: October 21, 2020 Time: 8:00am PDT Learning Objectives Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provider of continuing educ...
Date: October 20, 2020 Time: 5:00am (PDT), 8:00am (EDT), 2:00pm (CEST) With the COVID-19 pandemic as one of the biggest challenges to our modern world, Bruker has taken an active part suppor...
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
DATE: October 14, 2020 TIME: 10:00am PT Do you need help in planning your drug testing protocols? Did you know that a “one size fits all” approach to drug testing does not apply...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
Date: October 13, 2020 Time: 5:00am (PDT), 8:00am (EDT) Dr. Markus Kostrzewa shall ellaborate the progress that has been made in Bruker Microbiology Research and Development, including new p...
DATE: October 09, 2020 TIME: 08:00am PT Traditional culture techniques, as the primary diagnostic tool for infectious diseases, are coming under scrutiny for failing to universally detect in...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
Follow
